| Literature DB >> 35163388 |
Gilda Aiello1,2, Francesca Rescigno3, Marisa Meloni3, Giovanna Baron2, Giancarlo Aldini2, Marina Carini2, Alfonsina D'Amato2.
Abstract
Carnosine is an endogenous β-alanyl-L-histidine dipeptide endowed with antioxidant and carbonyl scavenger properties, which is able to significantly prevent the visible signs of aging and photoaging. To investigate the mechanism of action of carnosine on human skin proteome, a 3D scaffold-free spheroid model of primary dermal fibroblasts from a 50-year-old donor was adopted in combination with quantitative proteomics for the first time. The label free proteomics approach based on high-resolution mass spectrometry, integrated with network analyses, provided a highly sensitive and selective method to describe the human dermis spheroid model during long-term culture and upon carnosine treatment. Overall, 2171 quantified proteins allowed the in-depth characterization of the 3D dermis phenotype during growth and differentiation, at 14 versus 7 days of culture. A total of 485 proteins were differentially regulated by carnosine at 7 days, an intermediate time of culture. Of the several modulated pathways, most are involved in mitochondrial functionality, such as oxidative phosphorylation, TCA cycle, extracellular matrix reorganization and apoptosis. In long-term culture, functional modules related to oxidative stress were upregulated, inducing the aging process of dermis spheroids, while carnosine treatment prevented this by the downregulation of the same functional modules. The application of quantitative proteomics, coupled to advanced and relevant in vitro scaffold free spheroids, represents a new concrete application for personalized therapies and a novel care approach.Entities:
Keywords: carnosine; dermis spheroids; high-resolution mass spectrometry; network analyses; oxidative stress
Mesh:
Substances:
Year: 2022 PMID: 35163388 PMCID: PMC8836079 DOI: 10.3390/ijms23031468
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1(A) Immunofluorescence for collagen type III (in red) on 3D whole mount tissues. Mag. 20×. (B) The 3D rendering of Z stack maximum projection: nuclei (stained in blue) and collagen type III signal (stained in red).
Figure 2Scatter plots of log2 ratio on x-axis against -log10 p value on y-axis of significantly quantified proteins. (A) Quantified proteins in human dermis spheroids over time, from 7 to 14 days (C14 vs. C7). (B) Quantified proteins in carnosine pre-treated dermis versus control at 7 days (PD7 vs. C7). Green color indicates downregulation (log2 ratio ≤ −0.55), red color represents upregulation (log2 ratio ≥ 0.55). Statistical parameters (p < 0.05; q < 0.05, q = FDR adjusted + value) were set to identify the differentially expressed proteins between samples.
Figure 3(A) Subcellular distribution of identified proteins. (B) Main pathways involving extracellular matrix organization and plasma membrane proteins.
Figure 4Functional module of matrix reorganization obtained by Reactome (a section of the entire picture) (Supplementary Figure S2). The brown color indicates all the extracellular and plasma proteins identified in analyses of controls and carnosine treated samples.
Extracellular matrix proteins in spheroids at 14 days versus ones at 7 days (CD14 vs. CD7) and carnosine treated spheroids at 7 days versus control spheroids (PD7 vs. CD7).
| Gene Name | Protein Name | Log2 C7/C14 | Log2 PD7/C7 | Location | ||
|---|---|---|---|---|---|---|
| TF | transferrin | 1.35 × 10−07 | 3.98 | 8.78 × 10−06 | 2.67 | Extracellular Space |
| COL6A3 | collagen type VI alpha 3 chain | 1.16 × 10−03 | 4.71 | 2.64 × 10−03 | 2.28 | Extracellular Space |
| STOML2 | stomatin like 2 | 2.77 × 10−02 | 1.36 | 5.00 × 10−05 | 2.13 | Plasma Membrane |
| FBN1 | fibrillin 1 | 3.61 × 10−02 | 2.01 | 1.11 × 10−01 | 1.93 | Extracellular Space |
| INS | insulin | 1.42 × 10−02 | 1.53 | 4.84 × 10−04 | 1.56 | Extracellular Space |
| SLC1A5 | solute carrier family 1 member 5 | 7.57 × 10−04 | 1.54 | 7.41 × 10−04 | 1.46 | Plasma Membrane |
| TPBG | trophoblast glycoprotein | 2.28 × 10−03 | 1.20 | 5.37 × 10−04 | 1.45 | Plasma Membrane |
| MFAP2 | microfibril associated protein 2 | 1.31 × 10−02 | 1.37 | 8.77 × 10−03 | 1.42 | Extracellular Space |
| GPNMB | glycoprotein nmb | 1.88 × 10−02 | 1.17 | 1.45 × 10−02 | 1.36 | Plasma Membrane |
| MIF | macrophage migration inhibitory factor | 2.26 × 10−02 | −0.49 | 5.21 × 10−03 | 0.94 | Extracellular Space |
| RAP2B | RAP2B. member of RAS oncogene family | 7.48 × 10−03 | 0.94 | 3.60 × 10−03 | 0.93 | Plasma Membrane |
| MME | membrane metalloendopeptidase | 5.19 × 10−02 | 0.76 | 5.59 × 10−02 | 0.89 | Plasma Membrane |
| CCDC47 | coiled-coil domain containing 47 | 7.94 × 10−02 | 0.91 | 4.60 × 10−02 | 0.72 | Extracellular Space |
| LAMTOR1 | late endosomal/lysosomal adaptor. MAPK and MTOR activator 1 | 1.78 × 10−02 | 1.31 | 1.46 × 10−01 | 0.70 | Plasma Membrane |
| BSG | basigin (Ok blood group) | 8.96 × 10−01 | 0.03 | 5.41 × 10−04 | 0.69 | Plasma Membrane |
| EMILIN2 | elastin microfibril interfacer 2 | 2.38 × 10−03 | 1.33 | 2.57 × 10−02 | 0.69 | Extracellular Space |
| MANF | mesencephalic astrocyte derived neurotrophic factor | 8.26 × 10−02 | 0.32 | 7.10 × 10−03 | 0.68 | Extracellular Space |
| ITGAV | integrin subunit alpha V | 6.55 × 10−03 | 0.50 | 2.10 × 10−02 | 0.63 | Plasma Membrane |
| LOXL1 | lysyl oxidase like 1 | 8.17 × 10−01 | 0.05 | 2.39 × 10−03 | 0.62 | Extracellular Space |
| CD248 | CD248 molecule | 3.71 × 10−03 | 0.81 | 6.14 × 10−02 | 0.62 | Plasma Membrane |
| SCARB2 | scavenger receptor class B member 2 | 3.63 × 10−03 | 1.10 | 1.65 × 10−01 | 0.60 | Plasma Membrane |
| NT5E | 5’-nucleotidase ecto | 3.15 × 10−05 | 1.10 | 9.54 × 10−02 | 0.59 | Plasma Membrane |
| ARL8B | ADP ribosylation factor like GTPase 8B | 9.04 × 10−02 | 0.66 | 1.07 × 10−01 | 0.57 | Plasma Membrane |
| THY1 | Thy-1 cell surface antigen | 4.21 × 10−04 | 1.30 | 1.61 × 10−01 | 0.55 | Plasma Membrane |
| COL6A2 | collagen type VI alpha 2 chain | 1.60 × 10−02 | 0.85 | 1.22 × 10−01 | 0.52 | Extracellular Space |
| LAMP1 | lysosomal associated membrane protein 1 | 2.76 × 10−01 | 0.36 | 5.61 × 10−02 | 0.52 | Plasma Membrane |
| ESYT2 | extended synaptotagmin 2 | 2.21 × 10−02 | 0.66 | 1.22 × 10−01 | 0.50 | Plasma Membrane |
| CD81 | CD81 molecule | 4.55 × 10−03 | 0.88 | 1.43 × 10−01 | 0.46 | Plasma Membrane |
| CD44 | CD44 molecule (Indian blood group) | 1.80 × 10−02 | 0.82 | 2.69 × 10−01 | 0.44 | Plasma Membrane |
| EMILIN1 | elastin microfibril interfacer 1 | 1.91 × 10−02 | 0.72 | 5.22 × 10−02 | 0.36 | Extracellular Space |
| HLA-A | major histocompatibility complex. class I. A | 3.99 × 10−03 | 0.89 | 2.65 × 10−01 | 0.35 | Plasma Membrane |
| MARCKS | myristoylated alanine rich protein kinase C substrate | 9.03 × 10−02 | −0.26 | 9.51 × 10−04 | −0.77 | Plasma Membrane |
| LAMP2 | lysosomal associated membrane protein 2 | 7.14 × 10−01 | 0.07 | 1.63 × 10−02 | −0.77 | Plasma Membrane |
| PLPP3 | phospholipid phosphatase 3 | 8.12 × 10−01 | 0.03 | 2.23 × 10−02 | −0.85 | Plasma Membrane |
| FN1 | fibronectin 1 | 2.20 × 10−09 | −0.84 | 2.50 × 10−01 | −1.46 | Extracellular Space |
Figure 5Functional modules related to pathways of reactive oxygen species obtained by IPA. (A) dermis spheroids at 14 days related to those at 7 days. (B) Carnosine treated spheroids at 7 days versus controls at 7 days. The orange and blue color of the central hub indicate an up and downregulation of the module, respectively, while red and green indicate the up and downregulated proteins, respectively.